47.57USD-0.54%Mkt Cap: —P/E: 7.031d ago
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which c…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value3.09B $
Revenue (TTM)18.67M $
Gross Profit-114.71M $
Net Income (TTM)-252.21M $
Revenue/Share0.2990 USD
Last Price47.57 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees221
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)7.03
P/E (Forward)—
PEG—
EV/EBITDA-16.91
EV/Revenue165.68
P/S—
P/B10.41
EPS (TTM)6.89
EPS (Forward)—
52W Range
46.0363% of range48.49
52W High48.49 USD
52W Low46.03 USD
Profitability
Gross Margin0.00%
Oper. Margin-872.23%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-157.61%
ROA-15.72%
Growth
Revenue Growth11.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-160.79M $
CapEx (TTM)—
FCF Margin-415.49%
FCF Yield—
Net Debt-258.17M $
Net Debt/EBITDA1.41
Balance Sheet
Debt/Equity170.40
Current Ratio10.01
Quick Ratio9.79
Book Value/Sh4.674 USD
Cash/Share11.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.37.25M
Float57.52M
Insiders1.26%
Institutions96.19%
Technical
SMA 505.839 (+714.7%)
SMA 2009.365 (+408.0%)
Beta0.94
S&P 52W Chg18.16%
Avg Vol (30d)985
Avg Vol (10d)2.08K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—